Generate Biomedicines, Inc.
GENBDrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
23dMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
How GENB's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GB-0895 | Phase 3 | Severe Asthma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Generate Biomedicines, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Generate Biomedicines, Inc.'s (GENB) pipeline across Phase 3. Its lead program is GB-0895 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Generate Biomedicines, Inc.'s next FDA catalyst?→
Generate Biomedicines, Inc.'s (GENB) next tracked catalyst is a Phase 3 expected June 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GENB biotech catalysts?→
Add GENB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Generate Biomedicines, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.